Metagenomi

MGX

Market cap $69.8M

Overview Fund Activity

1.86 USD

-0.03

1.59%

At close Updated Sep 12, 4:00 PM EDT

1 day

-1.59%

5 days

-3.12%

1 month

-1.06%

3 months

28.28%

6 months

-9.27%

Year to date

-50.92%

1 year

-30.86%

5 years

-81.96%

10 years

-81.96%

About: Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

Employees: 171

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

10% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 21

4.86% less ownership

Funds ownership: 25.46% [Q1] → 20.6% (-4.86%) [Q2]

10% less funds holding

Funds holding: 77 [Q1] → 69 (-8) [Q2]

21% less capital invested

Capital invested by funds: $13.2M [Q1] → $10.4M (-$2.78M) [Q2]

31% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 26

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

276% upside

Avg. target

$10

438% upside

High target

$12

545% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Mitchell S. Kapoor	$7	Buy Reiterated	19 Aug 2025
Chardan Capital Geulah Livshits	$11	Buy Maintained	15 Aug 2025
Wells Fargo Yanan Zhu	$12	Overweight Maintained	14 Aug 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

Metagenomi (MGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.29 per share a year ago.

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $ 205.0 million in cash, cash equivalents and available-for-sale marketable securities as of June 30, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today reported financial results for the quarter ended June 30, 2025, and provided business updates.

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors.

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders -

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

Zacks Investment Research

Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates

Metagenomi (MGX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.19 per share a year ago.

Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety profile

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

Metagenomi to Present at Upcoming Scientific Meetings

EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: an oral presentation at TIDES USA 2025, taking place May 19-22, 2025, at the Manchester Grand Hyatt San Diego, and three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting, taking place May 13-17, 2025, in New Orleans, LA and virtually.

Metagenomi to Present at Upcoming Scientific Meetings

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells Expression of the compact CAST system from a single 'all-in-one' mRNA design represents a first-in-class approach to simplifying delivery for therapeutic applications Additional updates on further advancements in novel large gene integration technology anticipated in 2025 EMERYVILLE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced a publication in the journal Nature Communications describing its novel, compact CAST system for large, targeted gene integration into the human genome.

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will host one-on-one investor meetings at the conference.

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

See News Rankings

Charts implemented using Lightweight Charts™